Chuyển sang chế độ ngoại tuyến với ứng dụng Player FM !
What makes a successful regulatory submission from a clinical trial perspective? (Part 1/3) – MedTech CRO: Regulatory Expertise Series
Manage episode 444532922 series 2688337
*This video is part of our educational video series on clinical trials. Clips will cover three key areas: clinical trial strategy, clinical trial execution, and regulatory expertise in clinical trials. Please reach out to RQM+ if you need support with clinical trials.*
In part one of a three part series, Jaishankar Kutty, Ph.D. hosts former FDA lead reviewer Ryan Randall and ex-BSI clinical compliance head Amie Smirthwaite (current RQM+ Senior VP of Scientific Affairs) to unpack the intricacies of successful regulatory submissions in clinical trials.
Key topics covered:
- Essential stakeholders in the clinical trial approval process for both US and EU markets
- The importance of early engagement with regulatory bodies and payers
- Reviewer approaches to clinical data sets and benefit-risk analyses
- Strategies for navigating failed primary endpoints
- The balance between statistical and clinical significance in regulatory decision-making
- Differences in approach between MDD and MDR in the EU
- The impact of study design and protocol adherence on regulatory review
These experts provide invaluable insights into the mindset of regulatory reviewers, offering guidance on how to present clinical data effectively and navigate complex regulatory landscapes.
Whether you're a seasoned professional or new to the field, this discussion offers crucial perspectives on optimizing your regulatory submission strategy for medical devices and IVDs in both the US and EU markets.
Don't miss this opportunity to learn from top industry experts and enhance your understanding of the regulatory review process in clinical trials!
--
📝 If you'd like to speak with us directly about how we might be able to support you and your organization, you're welcome to use our contact form.
185 tập
Manage episode 444532922 series 2688337
*This video is part of our educational video series on clinical trials. Clips will cover three key areas: clinical trial strategy, clinical trial execution, and regulatory expertise in clinical trials. Please reach out to RQM+ if you need support with clinical trials.*
In part one of a three part series, Jaishankar Kutty, Ph.D. hosts former FDA lead reviewer Ryan Randall and ex-BSI clinical compliance head Amie Smirthwaite (current RQM+ Senior VP of Scientific Affairs) to unpack the intricacies of successful regulatory submissions in clinical trials.
Key topics covered:
- Essential stakeholders in the clinical trial approval process for both US and EU markets
- The importance of early engagement with regulatory bodies and payers
- Reviewer approaches to clinical data sets and benefit-risk analyses
- Strategies for navigating failed primary endpoints
- The balance between statistical and clinical significance in regulatory decision-making
- Differences in approach between MDD and MDR in the EU
- The impact of study design and protocol adherence on regulatory review
These experts provide invaluable insights into the mindset of regulatory reviewers, offering guidance on how to present clinical data effectively and navigate complex regulatory landscapes.
Whether you're a seasoned professional or new to the field, this discussion offers crucial perspectives on optimizing your regulatory submission strategy for medical devices and IVDs in both the US and EU markets.
Don't miss this opportunity to learn from top industry experts and enhance your understanding of the regulatory review process in clinical trials!
--
📝 If you'd like to speak with us directly about how we might be able to support you and your organization, you're welcome to use our contact form.
185 tập
Όλα τα επεισόδια
×Chào mừng bạn đến với Player FM!
Player FM đang quét trang web để tìm các podcast chất lượng cao cho bạn thưởng thức ngay bây giờ. Đây là ứng dụng podcast tốt nhất và hoạt động trên Android, iPhone và web. Đăng ký để đồng bộ các theo dõi trên tất cả thiết bị.